An enhanced therapeutic effect of F8-IL2 (an antibody-IL2 fusion protein) bombinated with anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies was observed in immunocompetent mice bearing CT26 tumours (116). The gene discussed is IL2; the disease is neoplasm.